Congratulations! [Software]

posted by Helmut Homepage – Vienna, Austria, 2019-12-01 14:50 (1164 d 00:42 ago) – Posting: # 20903
Views: 3,244

Hi PharmCat,

my deepest respect for the work you have done! Julia is a nasty beast (IMHO, more than SAS and R combined). :-D

❝ […] Covariance structure: CSH (Type C).


OK, the FDA’s guidance states:

    PROC MIXED;
    CLASSES SEQ SUBJ PER TRT;
    MODEL Y = SEQ PER TRT/ DDFM=SATTERTH;
    RANDOM TRT/TYPE=FA0(2) SUB=SUBJ G;
    REPEATED/GRP=TRT SUB=SUBJ;
    ESTIMATE 'T vs. R' TRT 1 -1/CL ALPHA=0.1;

In the Random statement, TYPE=FA0(2) could possibly be replaced by TYPE=CSH.


(my emphasis)

In some of our reference datasets (and terrible ones posted by John in the forum) of the partial replicate TRR|RTR|RRT we ran into convergence issues with FA0(2) but never with FA0(1) and CSH. Do I understand correctly that you have given up to support partial replicates as all?

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
20 visitors (0 registered, 20 guests [including 7 identified bots]).
Forum time: 15:32 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5